Literature DB >> 20690046

Epstein-barr virus-associated smooth muscle tumor of the larynx: report of a rare case mimicking leiomyosarcoma.

Jingxiang Huang1, Kwok Seng Loh, Fredrik Petersson.   

Abstract

We present a patient (male 54 years) with a history of renal transplant who 14 years post transplantation developed a symptomatic (stridor) laryngeal Epstein Barr virus (EBV)-associated smooth muscle tumor (EBV-SMT) in the absence of concomitant disease elsewhere. Nine years post transplantation the patient developed a subcutaneous EBV-SMT tumor located on the calf. The laryngeal tumor displayed low-grade nuclear atypia and was infiltrating into the surrounding soft tissue, focally ulcerating through the overlying epithelium. Histologic features included: neoplastic cells with myoid differentiation, a component of primitive appearing small mesenchymal cells with hyperchromatic nuclei, mitotic activity, intralesional small to medium sized blood vessels and T-lymphocytes. Both the myoid and small cell mesenchymal components strongly expressed smooth muscle actin and h-caldesmon, but not desmin, cytokeratins, CD34 or S-100 protein. There was strong positive nuclear reaction for EBV-RNA on in situ hybridization (EBER). No other tumor was detected on clinical and radiological examinations and no evidence of tumor in other sites, over 8 months of follow-up, till death was detected. This case emphasizes the importance of considering this pathologic entity when solitary smooth muscle actin-expressing tumors are encountered in the larynx of immunocompromised patients.

Entities:  

Mesh:

Year:  2010        PMID: 20690046      PMCID: PMC2996495          DOI: 10.1007/s12105-010-0201-7

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  17 in total

Review 1.  Leiomyosarcoma of the larynx.

Authors:  J Rimmer; C E B Giddings; S Mady
Journal:  J Laryngol Otol       Date:  2006-02       Impact factor: 1.469

2.  Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients.

Authors:  Andrea T Deyrup; Victor K Lee; Charles E Hill; Wah Cheuk; Han Chong Toh; Sittampalam Kesavan; Errol Wei'en Chan; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2006-01       Impact factor: 6.394

3.  Leiomyosarcoma of the larynx: critical analysis of the diagnostic role played by immunohistochemistry.

Authors:  Gino Marioni; Claudia Staffieri; Filippo Marino; Alberto Staffieri
Journal:  Am J Otolaryngol       Date:  2005 May-Jun       Impact factor: 1.808

Review 4.  Epstein-Barr virus-associated multicentric leiomyosarcoma in an adult patient after heart transplantation: case report and review of the literature.

Authors:  H Rogatsch; H Bonatti; A Menet; C Larcher; H Feichtinger; S Dirnhofer
Journal:  Am J Surg Pathol       Date:  2000-04       Impact factor: 6.394

5.  Smooth muscle tumours of the larynx.

Authors:  D C McKiernan; G W Watters
Journal:  J Laryngol Otol       Date:  1995-01       Impact factor: 1.469

6.  Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS.

Authors:  K L McClain; C T Leach; H B Jenson; V V Joshi; B H Pollock; R T Parmley; F J DiCarlo; E G Chadwick; S B Murphy
Journal:  N Engl J Med       Date:  1995-01-05       Impact factor: 91.245

7.  The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation.

Authors:  E S Lee; J Locker; M Nalesnik; J Reyes; R Jaffe; M Alashari; B Nour; A Tzakis; P S Dickman
Journal:  N Engl J Med       Date:  1995-01-05       Impact factor: 91.245

8.  Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx.

Authors:  G Klein; B C Giovanella; T Lindahl; P J Fialkow; S Singh; J S Stehlin
Journal:  Proc Natl Acad Sci U S A       Date:  1974-12       Impact factor: 11.205

9.  Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases.

Authors:  C M Coffin; J Watterson; J R Priest; L P Dehner
Journal:  Am J Surg Pathol       Date:  1995-08       Impact factor: 6.394

Review 10.  Epstein-Barr virus-associated lymphoproliferative disorders.

Authors:  Sherif A Rezk; Lawrence M Weiss
Journal:  Hum Pathol       Date:  2007-09       Impact factor: 3.466

View more
  6 in total

Review 1.  Epstein-Barr Virus-Associated Smooth Muscle Tumors of Larynx: A Clinicopathologic Study and Comprehensive Literature Review of 12 Cases.

Authors:  Rumeal D Whaley; Lester D R Thompson
Journal:  Head Neck Pathol       Date:  2021-04-23

Review 2.  Sarcomas other than Kaposi sarcoma occurring in immunodeficiency: interpretations from a systematic literature review.

Authors:  Kishor Bhatia; Meredith S Shiels; Alexandra Berg; Eric A Engels
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.915

3.  Laryngeal Epstein-Barr Virus-Associated Smooth Muscle Tumor in an Undernourished Child.

Authors:  Ciro Dantas Soares; Roman Carlos; Juan Pablo Díaz Molina; Thayná Melo de Lima Morais; Oslei Paes de Almeida
Journal:  Head Neck Pathol       Date:  2018-08-17

4.  A case of laryngeal leiomyosarcoma and review of the literature.

Authors:  Ömer Tarik Selçuk; Levent Renda; Bekir Erol; Üstün Osma; Hülya Eyigor; Hülya Öztürk
Journal:  Ann Maxillofac Surg       Date:  2015 Jul-Dec

5.  A Case of Epstein-Barr Virus-Associated Leiomyosarcoma Concurrently With Posttransplant Lymphoproliferative Disorders After Renal Transplantation.

Authors:  Naohiro Aida; Taihei Ito; Michihiro Maruyama; Kenichi Saigo; Naotake Akutsu; Hiromichi Aoyama; Hiroshi Kitamura; Takashi Kenmochi
Journal:  Clin Med Insights Case Rep       Date:  2019-07-31

Review 6.  Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes.

Authors:  Gail E Reid; Joseph P Lynch; Samuel Weigt; David Sayah; John A Belperio; Shellee A Grim; Nina M Clark
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.